ICON (ICLR) Hisse Fiyat
ICON Fiyat
ICON, son 19 yılda gelirini yıllık %16,5 artırarak 8,25 Md USD seviyesine taşıdı. Hisse başına kâr, son 19 yılda yıllık %4,4 büyüdü. ICON için net marj, %2,8 ile birkaç yıl önceki %2,8 seviyesine göre büyük ölçüde sabit kaldı. ICON için 12 aylık konsensüs fiyat hedefi 175,00 USD; bu, hissenin bugünkü fiyatının yaklaşık %17,2 altında bir seviyeye denk geliyor. 24 analistten 15 tanesi hisse için alım öneriyor — genel konsensüs: Al.
ICON hisse senedi fiyatı
Bu verilere Eulerpool API üzerinden ulaşın
Ayda 100.000 ücretsiz istek · kredi kartı yok
ICON iş modeli ve hisse analizi
ICON hakkında sık sorulan sorular
The main competitors of ICON PLC in the market include other Contract Research Organizations (CROs) such as Covance Inc., QuintilesIMS Holdings Inc., and PAREXEL International Corporation. These companies provide similar services and solutions in the clinical research and development industry, offering competition to ICON PLC's global presence and expertise.
ICON PLC, also known as ICON, is a well-established global provider of clinical research and development services to the pharmaceutical, biotechnology, and medical device industries. Founded in 1990 in Dublin, Ireland, ICON has since expanded its operations worldwide, with offices in over 40 countries. The company offers various services, including clinical trial management, data management and analysis, regulatory support, and post-market surveillance. With a strong focus on innovation and expertise, ICON has successfully collaborated with numerous healthcare organizations to accelerate the development of innovative therapies and improve patient outcomes. Due to its vast experience and industry reputation, ICON PLC continues to be a trusted partner in advancing healthcare solutions globally.
The business model of ICON PLC is centered around providing clinical research services to pharmaceutical, biotechnology, and medical device companies. ICON offers a range of services including clinical trial management, data collection and analysis, regulatory consulting, and patient recruitment. They help their clients with the development and commercialization of new drugs and treatments by conducting clinical trials and ensuring regulatory compliance. With a strong focus on innovation and expertise in the field, ICON PLC has established itself as a trusted partner for the life sciences industry.
ICON PLC is primarily active in the pharmaceutical, biotechnology, and medical device industries.
ICON PLC, a leading clinical research organization, has achieved significant milestones throughout its history. The company's accomplishments include becoming a key player in the development and execution of clinical trials worldwide. ICON PLC has successfully expanded its global footprint, delivering exceptional services in over 100 countries. With a strong focus on innovation and technology, the company has pioneered industry-leading solutions to enhance clinical trial processes and improve patient outcomes. ICON PLC's dedication to excellence has resulted in numerous accolades and recognition within the pharmaceutical and biotechnology industries. By consistently delivering high-quality results and establishing strategic partnerships, ICON PLC has solidified its reputation as a trusted and influential player in the field of clinical research.
ICON PLC is primarily present in various countries and regions globally. With a strong international presence, the company operates in multiple key markets, including the United States, United Kingdom, Ireland, Europe, Asia-Pacific, and the Middle East. This global footprint enables ICON PLC to cater to clients worldwide and deliver its comprehensive range of professional services.
ICON PLC is a leading global provider of clinical research services to pharmaceutical, biotechnology, and medical device industries. ICON PLC is guided by a set of core values and corporate philosophy that focuses on innovation, integrity, collaboration, and excellence. The company's commitment to delivering high-quality research and development solutions, while maintaining ethical practices, has made it a trusted partner for successful clinical trials. With its dedication to advancing healthcare and improving patient outcomes, ICON PLC continues to be a respected and influential player in the industry.
Analistler şu anda ICON hissesi için ortalama 170,64 USD hedef fiyat belirliyor (medyan: 175,00 USD); bu, son fiyata göre -19,3 % anlamına gelir. Konsensüs 24 analist notuna dayanır.
24 analist şu anda ICON hissesini değerlendiriyor: 15 al, 8 tut, 1 sat öneriyor. 2026 için analistler ICON şirketinin 8,16 Md USD gelir ve 11,47 USD hisse başına kâr üretmesini bekliyor.
Güncel döviz kuruyla ICON hissesi 189,39 EUR (211,36 USD) seviyesindedir.
ICON hissesi (ICLR) 4 borsada işlem görür, bunlar arasında: NASDAQ (ICLR), Frankfurt (IJF.F), München (IJF.MU), Düsseldorf (IJF.DU).
ICON plc is a leading global company in the field of clinical research and development of pharmaceuticals. It offers a wide range of services in clinical trials, consulting, strategy development, laboratory analysis, and data management. The company is divided into three main business areas: clinical development services, laboratory analysis, and data management. It works closely with its customers and partners to develop groundbreaking medications and treatments. ICON is known for its Enterprise Laboratory Information Management System (LIMS) and EDC solutions. It has a robust business model and is well-positioned for future growth.
beklenen'nin ICON hasılatı 8,16 Md USD'dir. Bu rakam, mevcut finansal verilere dayanmakta ve şirketin iş performansını yansıtmaktadır.
beklenen'nin ICON karı 878,58 M USD'dir. Net kar, tüm giderleri düştükten sonra şirketin kârlılığını gösterir.
ICON'nin Fiyat/Kazanç (F/K) oranı şu anda 18,42'dir. F/K oranı, cari hisse fiyatını hisse başına kazançla karşılaştırır ve yatırımcıların ICON hisse senedinin değerlemesini değerlendirmelerine yardımcı olur.
ICON'nin Fiyat/Satış (F/S) oranı şu anda 1,98'dir. F/S oranı, pazar kapitalizasyonunu yıllık gelirle karşılaştırır ve ICON hisse senedinin değerleme metriği olarak hizmet eder.
ICON'nin Eulerpool Kalite Puanı 2/10'dur.
ICON'nin ISIN'i IE0005711209'dir. ISIN (Uluslararası Menkul Kıymetler Kimlik Numarası), menkul kıymetler için küresel olarak benzersiz bir tanımlayıcıdır.
ICON'nin WKN'i 932242'dir. WKN (Wertpapierkennnummer), menkul kıymetleri tanımlamak için kullanılan altı haneli bir Alman kimlik numarasıdır.
ICON'nin ticker'ı ICLR'dir. Ticker sembolü, ICON hisseleri borsada işlem görmek için kullanılır.
ICON Hissesi
ICON'nin tüm temel göstergeleri ve derinlemesine analizi
ICON hissesine yönelik aktienanalizimiz, satış, kar, P/E oranı, P/S oranı, EBIT gibi önemli mali kriterleri içermekte olup, dividende bilgilerini de ele almaktadır. Ayrıca, hisseler, piyasa değeri, borçlar, özsermaye ve ICON şirketin yükümlülükleri gibi konuları incelemekteyiz. Bu konular hakkında daha detaylı bilgilere ihtiyacınız varsa, web sitemizin alt sayfalarında kapsamlı analizler sunuyoruz: